This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Eric D. Peterson, MD, MPH; Tracy Y. Wang, MD, MS

JAMA. 2008;299(14):1718-1720.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The debates of 2008 have already been quite intense. During this election year, politicians and pundits alike, reviewing the same set of information, have formulated remarkably different conclusions and recommendations for national policy. The field of preventive cardiology has likewise been witness to its own debate. Spurred by a series of important yet somewhat unexpected clinical trial results, the question of "how low to go" in cardiovascular risk-factor modification has been hotly disputed.

This debate is not new and traditionally has been waged between the "true believers," those with a strong a priori conviction that more aggressive pharmacological treatment will reduce future events, and the "therapeutic nihilists," those who require unequivocal proof before acceptance. In recent years, the true believers have had the upper hand. Epidemiologic data have consistently concluded that lower levels of lipids, blood pressure, and glucose all . . . [Full Text of this Article]

Author Affiliations: Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. Dr Peterson is also Contributing Editor, JAMA.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Barbara V. Howard, Mary J. Roman, Richard B. Devereux, Jerome L. Fleg, James M. Galloway, Jeffrey A. Henderson, Wm. James Howard, Elisa T. Lee, Mihriye Mete, Bryce Poolaw, Robert E. Ratner, Marie Russell, Angela Silverman, Mario Stylianou, Jason G. Umans, Wenyu Wang, Matthew R. Weir, Neil J. Weissman, Charlton Wilson, Fawn Yeh, and Jianhui Zhu
JAMA. 2008;299(14):1678-1689.
ABSTRACT | FULL TEXT